Higher Framingham steatosis index is associated with prevalent breast cancer in women: cross-sectional evidence from NHANES 1999–2018 and an exploratory hospital-based dataset - Takeaways - MDSpire

Higher Framingham steatosis index is associated with prevalent breast cancer in women: cross-sectional evidence from NHANES 1999–2018 and an exploratory hospital-based dataset

  • By

  • Shuling Tang

  • Yong Mo

  • Tiansheng Su

  • Guangxiang Huang

  • Jiachao Lu

  • Jianbin Bi

  • Hui Li

  • Ligen Mo

  • Jun Yan

  • July 8, 2026

  • 0 min

Share

  • 1

    The study analyzed the association between the Framingham Steatosis Index (FSI) and prevalent breast cancer in women using NHANES data from 1999 to 2018.

  • 2

    Among 21,042 women, 2.5% reported a history of breast cancer, with each 1-unit increase in FSI linked to higher odds of prevalent breast cancer.

  • 3

    The association between FSI and breast cancer was attenuated after adjusting for age, indicating age's significant role in this relationship.

  • 4

    Higher FSI quartiles correlated with increased odds of prevalent breast cancer, but the continuous association varied in an exploratory hospital dataset.

  • 5

    FSI should be viewed as a composite marker of metabolic-hepatic burden rather than a direct diagnostic measure of hepatic steatosis.

Original Source(s)

Higher Framingham steatosis index is associated with prevalent breast cancer in women: cross-sectional evidence from NHANES 1999–2018 and an exploratory hospital-based dataset

  • by Shuling Tang, Yong Mo, Tiansheng Su, Guangxiang Huang, Jiachao Lu, Jianbin Bi, Hui Li, Ligen Mo, Jun Yan

  • July 8, 2026

Related Content

Primary classical Hodgkin lymphoma of breast presenting as recurrent breast abscess in a non-lactating woman: a case report and literature review

Repurposing tricyclic drugs as cancer therapeutics: comparative analysis of antitumorigenic effects of chlorpromazine, amitriptyline and imipramine

Case report: Secretory carcinoma of the breast with ETV6-NTRK3 fusion: clinicopathological features and molecular confirmation by FISH in two cases